Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are:
Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:
In this single-center study, the investigators evaluated patients diagnosed with acute kidney injury (AKI) who underwent emergency hemodialysis. AKI has a high mortality rate and can be accompanied by many complications. Progression to chronic kidney disease is one of the most important of these complications. Identifying prognostic determinants in patients receiving hemodialysis treatment due to AKI can provide significant benefits for clinical practice. In this study, the investigators aimed to determine the prognosis in this patient group using some vascular-endothelial markers. The investigators collected serum samples before hemodialysis from AKI patients indicated for hemodialysis and measured the levels of Activin A, Nostrin, and Angiopoetin-2. The investigators aimed to evaluate the relationship between these levels and parameters such as in-hospital mortality, 6-month mortality, and weaning from hemodialysis after 6 months or hemodialysis dependence.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AKI-HD GROUP | Other | Acute kidney injury (undergoing hemodialysis) arm. The only group in the study. Measurement of serum Activin A, serum Nostrin, serum Angiopoetin-2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Serum samples before hemodialysis. | Diagnostic Test | Except from taking a venous blood sample there are no interventions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD) | Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status. | From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days) |
| Measure | Description | Time Frame |
|---|---|---|
| All cause mortality and need for hemodialysis or weaning from hemodialysis | Patients who were discharged from the hospital after the initiation of hemodialysis were followed up for 180 days in terms of discontinuing or continuing hemodialysis treatment and survival/death status. | 180 days after the initiation of first hemodialysis session |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alper Alp, Assoc Prof,MD | Muğla Sıtkı Koçman University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mugla Sitki Kocman University | Muğla | Menteşe | 48000 | Turkey (Türkiye) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38603667 | Background | Erfurt S, Lauxmann M, Asmus K, Oess S, Patschan D, Hoffmeister M. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. PLoS One. 2024 Apr 11;19(4):e0299131. doi: 10.1371/journal.pone.0299131. eCollection 2024. | |
| 22751148 | Background | Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, Munn AL, Muller-Esterl W, Popp R, Fleming I, Jungblut B, Hoffmeister M, Oess S. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO J. 2012 Aug 1;31(15):3309-22. doi: 10.1038/emboj.2012.176. Epub 2012 Jun 29. |
Not provided
Not provided
There is no plan to share individual data from this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 27372077 | Background | Robinson-Cohen C, Katz R, Price BL, Harju-Baker S, Mikacenic C, Himmelfarb J, Liles WC, Wurfel MM. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care. 2016 Jul 3;20(1):207. doi: 10.1186/s13054-016-1385-3. |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |